Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.77 |
| ▸ | CASP1 | P29466 | 2/20 | 0.77 |
| ▸ | HBB | P68871 | 2/20 | 0.77 |
| ▸ | NPC1 | O15118 | 1/20 | 0.77 |
| ▸ | RAB9A | P51151 | 1/20 | 0.77 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.62 |
| ▸ | CHKA | P35790 | 1/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532373 | 0.87 | MAPT (1.00) | MAPTSMN1; SMN2MEN1KMT2AALOX15 | |
| SCHEMBL305456 | 0.87 | MAPT (1.00) | MAPTSMN1; SMN2MEN1KMT2AALOX15 | |
| SCHEMBL6892241 | 0.86 | ALDH1A1 (0.65) | MAPTSMN1; SMN2MEN1KMT2AALOX15 | |
| Bromide SCHEMBL27884858 | 0.85 | MAPT (0.96) | MAPTSMN1; SMN2MEN1KMT2AALOX15 | |
| Bromide SCHEMBL27779245 | 0.85 | MAPT (0.96) | MAPTSMN1; SMN2MEN1KMT2AALOX15 | |
| Bromide SCHEMBL28824563 | 0.85 | MAPT (0.96) | MAPTSMN1; SMN2MEN1KMT2AALOX15 | |
| Hydrochloric Acid SCHEMBL9803944 | 0.85 | MAPT (0.96) | MAPTSMN1; SMN2MEN1KMT2AALOX15 | |
| Hydrochloric Acid SCHEMBL9803942 | 0.85 | MAPT (0.96) | MAPTSMN1; SMN2MEN1KMT2AALOX15 | |
| SCHEMBL8664726 | 0.78 | CHRM5 (1.00) | MAPTSMN1; SMN2MEN1KMT2AALOX15 | |
| SCHEMBL189 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037931-B2 | Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-02 | — | — | US | claimed |
| US-20060004195-A1 | Alpha,beta-unsaturated esters and acids by stereoselective dehydration | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-05 | — | — | US | disclosed |
| US-20050026903-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-03 | — | — | US | disclosed |
| US-20050020565-A1 | Pyrazole compound; gastrointestinal disorders; central nervous system disorders | JONES TODD K (US) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020565-A1 | Pyrazole compound; gastrointestinal disorders; central nervous system disorders | CCKAR, CCKBR, NPY1R | MAPT 2577/4885SMN1; SMN2 1459/4885MEN1 1705/4885 |
| US-20060004195-A1 | Alpha,beta-unsaturated esters and acids by stereoselective dehydration | CCKAR, CCKBR, FFAR1 | MAPT 4782/4885SMN1; SMN2 4607/4885MEN1 4171/4885 |
| US-20050026903-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GLP1R | MAPT 4745/4885SMN1; SMN2 4633/4885MEN1 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.